CN103717616B - 表皮生长因子受体基因中的突变 - Google Patents

表皮生长因子受体基因中的突变 Download PDF

Info

Publication number
CN103717616B
CN103717616B CN201280037669.7A CN201280037669A CN103717616B CN 103717616 B CN103717616 B CN 103717616B CN 201280037669 A CN201280037669 A CN 201280037669A CN 103717616 B CN103717616 B CN 103717616B
Authority
CN
China
Prior art keywords
seqidno
egfr
oligonucleotide
cetuximab
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280037669.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN103717616A (zh
Inventor
C·蒙塔古特维拉多特
J·阿尔巴内尔梅斯特雷斯
A·罗维拉古伦
B·贝略西略帕里西奥
A·达尔马赛斯马塞古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Original Assignee
Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM filed Critical Fundacio Institut Hospital del Mar dInvestigacions Mediques IMIM
Publication of CN103717616A publication Critical patent/CN103717616A/zh
Application granted granted Critical
Publication of CN103717616B publication Critical patent/CN103717616B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280037669.7A 2011-08-03 2012-08-02 表皮生长因子受体基因中的突变 Active CN103717616B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382270.4 2011-08-03
EP11382270A EP2554551A1 (en) 2011-08-03 2011-08-03 Mutations in the epidermal growth factor receptor gene
PCT/EP2012/065090 WO2013017645A1 (en) 2011-08-03 2012-08-02 Mutations in the epidermal growth factor receptor gene

Publications (2)

Publication Number Publication Date
CN103717616A CN103717616A (zh) 2014-04-09
CN103717616B true CN103717616B (zh) 2016-06-29

Family

ID=46640020

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280037669.7A Active CN103717616B (zh) 2011-08-03 2012-08-02 表皮生长因子受体基因中的突变

Country Status (12)

Country Link
US (1) US9765399B2 (https=)
EP (3) EP2554551A1 (https=)
JP (1) JP6149034B2 (https=)
KR (1) KR20140072035A (https=)
CN (1) CN103717616B (https=)
AU (1) AU2012292024A1 (https=)
BR (1) BR112014002373A2 (https=)
CA (1) CA2842270C (https=)
ES (1) ES2556468T3 (https=)
IN (1) IN2014CN00570A (https=)
RU (1) RU2014107908A (https=)
WO (1) WO2013017645A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP3805404A1 (en) 2014-05-13 2021-04-14 Board of Regents, The University of Texas System Gene mutations and copy number alterations of egfr, kras and met
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
US11015225B2 (en) * 2014-07-28 2021-05-25 Alberto Bardelli Method of treating cancer based on identifying mutations in the extracellular domain III of epidermal growth factor receptor gene
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
WO2016172584A1 (en) * 2015-04-24 2016-10-27 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
RU2626682C1 (ru) * 2016-07-20 2017-07-31 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования резистентности опухоли к таргетной терапии цетуксимабом у больных плоскоклеточным раком языка и слизистой дна полости рта
CN111499749B (zh) * 2020-03-13 2021-11-09 浙江大学 一种西妥昔单抗突变体及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275386A1 (en) 2004-03-01 2007-11-29 Ratain Mark J Polymorphisms in the Epidermal Growth Factor Receptor Gene Promoter
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
WO2006009694A2 (en) * 2004-06-14 2006-01-26 Imclone Sysetms Incorporated Crystal of egfr extracellular domain and cetuximab fab fragment and uses thereof
MX2007009963A (es) * 2005-02-24 2007-09-26 Amgen Inc Mutaciones del receptor del factor de crecimiento epidermico.
US7981606B2 (en) * 2005-12-21 2011-07-19 Roche Molecular Systems, Inc. Control for nucleic acid testing
AU2007329740B2 (en) * 2006-10-26 2014-05-01 Genentech, Inc. Genetic variations associated with tumors
WO2008088860A2 (en) 2007-01-18 2008-07-24 University Of Southern California Polymorphisms in the egfr pathway as markers for cancer treatment
US9090693B2 (en) * 2007-01-25 2015-07-28 Dana-Farber Cancer Institute Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
US8583380B2 (en) * 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1737162A (zh) * 2005-03-16 2006-02-22 南京中医药大学附属医院(江苏省中医院) 表皮生长因子受体(egfr)基因测序检测方法

Also Published As

Publication number Publication date
EP2739648A1 (en) 2014-06-11
KR20140072035A (ko) 2014-06-12
ES2556468T3 (es) 2016-01-18
RU2014107908A (ru) 2015-09-10
CA2842270C (en) 2019-10-29
JP6149034B2 (ja) 2017-06-14
BR112014002373A2 (pt) 2017-02-21
US20140170662A1 (en) 2014-06-19
CN103717616A (zh) 2014-04-09
EP2739648B1 (en) 2015-09-16
JP2014521342A (ja) 2014-08-28
AU2012292024A1 (en) 2014-02-27
WO2013017645A1 (en) 2013-02-07
IN2014CN00570A (https=) 2015-04-03
EP2554551A1 (en) 2013-02-06
EP2995623A1 (en) 2016-03-16
CA2842270A1 (en) 2013-02-07
US9765399B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
CN103717616B (zh) 表皮生长因子受体基因中的突变
Lee et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma
JP6513567B2 (ja) 肺腺癌の治療で使用するためのｍｅｔ、ｖｅｇｆｒ、およびｒｅｔの阻害剤
CN102859355B (zh) 通过检测kras突变和rtk表达水平来测定细胞对b-raf抑制剂治疗的敏感性
CN105074009B (zh) Egfr抑制剂的敏感性的预测方法
JP2019052187A (ja) ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
Oh et al. Clinical activity of pan-HER inhibitors against HER2-mutant lung adenocarcinoma
CN112912403A (zh) 治疗肿瘤的方法
TW201902509A (zh) Erbb2/her2突變
CN105848678A (zh) 核酸生物标志物及其用途
Toyokawa et al. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance
KR102338510B1 (ko) 항-her2 치료제에 대한 동반진단 마커 및 이의 용도
US20210262037A1 (en) Methods of treating cancer based on identifying mutations in the extracellular domain iii of epidermal growth factor receptor gene
Inoue et al. FcγR and EGFR polymorphisms as predictive markers of cetuximab efficacy in metastatic colorectal cancer
KR20220152287A (ko) 투카티닙으로 her2 돌연변이 암을 치료하는 방법
EP3126520A1 (en) Biomarkers and use of met inhibitor for treatment of cancer
US12351878B2 (en) Identification of HER2 mutations in lung cancer and methods of treatment
Pender et al. Understanding lung cancer molecular subtypes
CA2695070A1 (en) Predictive marker for egfr inhibitor treatment
Dalmases Massegú Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer
Cushman-Vokoun Somatic Alterations and Targeted Therapy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant